Negocie Vir Biotechnology VIR

Venda
 Comprar

Gráfico VirBiotechnology ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

VirBiotechnology news

Últimas notícias

Mostrar mais
Frances Wang 2025 Maio 13, 16:00

XRP News Today: XRP Rises on Increased Bank Demand in the US

Cryptocurrencies
Tommy Yap 2025 Maio 13, 16:00

Morning Note: Tencent's Report in Focus; Gold Affected by Trade Optimism; Oil Stable

Morning Note China Commodities
Frances Wang 2025 Maio 12, 16:00

ADA crypto price forecast: What factors influence the price of Cardano?

Cryptocurrencies
Tommy Yap 2025 Maio 12, 16:00

Morning Note: Tariff Rollback Sparks Stock Rally; US CPI Watch; Bailey's Speech

Morning Note Equities
Tommy Yap 2025 Maio 12, 04:00

Morning Note: US Surplus Expected; Denmark Inflation; UK Retail Sales Forecast

Morning Note EUR
Frances Wang 2025 Maio 11, 16:00

How the US-China Trade War Influenced Global Commodity Markets?

Commodities
Tommy Yap 2025 Maio 09, 21:00

Week Ahead: U.S. Inflation Data in Spotlight

Forex Indices
Frances Wang 2025 Maio 08, 16:00

What Is Happening to the Bond Market: Bond Market Outlook 2025

Bonds

Info

Spread

0.03

Spread (%)

0.6849 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercado aberto

Quarta-feira

13:31 - 19:59

Segunda-feira

13:31-19:59

Terça-feira

13:31-19:59

Quinta-feira

13:31-19:59

Sexta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

731739200

Ações em circulação

138064000

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

Data Ex-Dividendos

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-4.23

Saiba mais sobre este instrumento

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot